ALMS — ALUMIS INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1847367 ·
Last close
$4.84
Market Cap
$628.33M
52W High
$31.35
52W Low
$4.70
ADV30
1,913,621
Next earnings
2026-11-12
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,907,000 — -99,076,000 -94,881,000 488,711,000 57,691,000 110,286,000
Jun 2026 1,662,000 — -107,031,000 -142,221,000 560,618,000 63,706,000 108,460,000
Mar 2026 1,741,000 — -98,409,000 -93,053,000 671,588,000 63,885,000 104,567,000
Dec 2025 1,929,000 — -96,445,000 -92,931,000 411,940,000 89,670,000 110,643,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-351,398,000
Investing CF
$-97,944,000
Financing CF
$360,934,000
CapEx
$-1,054,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.34
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,137,150,000
Inventory
—
Receivables
$3,860,000
ST Investments
$438,587,000
EBIT TTM
$-417,177,000
Pretax Income TTM
$-440,714,000
Interest Exp TTM
—
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,239,000
EBITDA
$-426,366,016
Free Cash Flow
$-212,242,128
Enterprise Value
$330,965,440
Total Cash
$431,337,984
Total Debt
$35,306,000
Shares Out
129,820,970
Trailing EPS
$-3.53
Book Value
$2.92
ROE
-110.9%
ROA
-55.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 24,050,000 -453,804,000 -243,325,000 411,940,000 110,643,000 301,297,000 -369,523,000
Dec 2024 0 -300,754,000 -294,233,000 340,992,000 80,888,000 260,104,000 -255,078,000
Dec 2023 0 -158,174,000 -154,993,000 89,612,000 428,872,000 -339,260,000 -129,975,000
Dec 2022 0 -113,850,000 -111,930,000 108,168,000 303,410,000 -195,242,000 -107,722,000

TTM Snapshot

Revenues TTM
$7,398,000
NetIncome TTM
$-438,957,000
OpCashFlow TTM
—
Assets (Latest)
$560,618,000
Forward EPS
$-2.95

Max Pain — expiry 2027-01-15

max pain strike: $7.00 · spot: $4.39 · call oi: 10,355 · put oi: 23,280
Expected Move to 2027-01-15: ±$3.15 (71.67%) — implied range $1.25 – $7.54 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
DSGN Design Therapeutics, Inc. $630.12M $9.84 —
OLMA Olema Oncology, Inc. $632.52M $7.22 —
ABUS Arbutus Biopharma Corp $620.84M $4.05 —
BCAX Bicara Therapeutics Inc. $637.32M $9.60 —
SVA SINOVAC BIOTECH LTD $642.44M $6.47 —

News headlines (Yahoo Finance, 1h cache)

Alumis (ALMS) Stock Fair Value Moves Lower After Mixed Analyst Views On LUMUS
2026-11-16 09:08 · Yahoo
Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
2026-11-12 21:05 · Yahoo
Alumis (ALMS) Faces Pressure After Clinical Results
2026-11-12 17:27 · Yahoo
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
2026-10-09 17:11 · Yahoo
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
2026-10-09 08:00 · Yahoo
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
2026-09-09 01:30 · Yahoo
Alumis to Participate in Upcoming September Investor Conferences
2026-09-04 12:00 · Yahoo
Is Alumis (ALMS) Overvalued After Its 121% One Year Return?
2026-09-03 14:10 · Yahoo
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy
2026-09-03 12:15 · Yahoo
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?
2026-09-03 11:06 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.